Michael Margolis, MD
NPI 1780844522 · Ophthalmology Physician · Aventura, FL
Enrolled with Medicare as Practitioner - Ophthalmology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1780844522
- Entity type
- Individual
- Primary specialty
- Ophthalmology PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Male
- Sole proprietor
- No
- License
- MD2013-0813 (NM)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
18 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
535 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Problem Focused Exam of Visual System92012 | 124 | $90 |
| Imaging of Retina92134 | 115 | $41 |
| Established Patient Complete Exam of Visual System92014 | 108 | $127 |
| New Patient Complete Exam of Visual System92004 | 67 | $151 |
| Exam of Visual Field With Extended Testing92083 | 43 | $64 |
| Imaging of Optic Nerve92133 | 41 | $35 |
| 2d Ultrasound Scan of Eye Tissue and Structures76512 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 23 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 273 | 105 |
| Cyclosporinebrand: Restasis | 97 | 40 |
| Prednisolone Acetate | 83 | 63 |
| Tobramycin/Dexamethasonebrand: Tobramycin-Dexamethasone | 72 | 62 |
| Neomycin/Polymyxin B/Dexamethabrand: Neomycin-Polymyxin-Dexameth | 68 | 53 |
| Timolol Maleate | 64 | 27 |
| Loteprednol Etabonate | 64 | 46 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$1,439 across 45 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2008-06-16
- Last updated
- 2024-03-22
- Certified
- 2024-03-22
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.